- Efficacy increases over time: Greater improvements were seen at 12 months vs 6 months across refractive and structural outcomes.
- Stronger effect in higher myopia: Children with more severe baseline myopia experienced the greatest treatment benefit.
- Structural safety appears stable short-term: No meaningful changes in anterior chamber depth, corneal thickness, or lens thickness were observed.
- Adverse events were mostly mild and transient: Common issues included brightness discomfort and afterimages, with no serious events reported.
- Long-term safety remains unclear: Retinal outcomes were insufficiently reported, highlighting the need for longer-term studies.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
